MY119276A - Pharmaceutical composition for immunomodulation based on peptides and adjuvants - Google Patents

Pharmaceutical composition for immunomodulation based on peptides and adjuvants

Info

Publication number
MY119276A
MY119276A MYPI97000683A MYPI9700683A MY119276A MY 119276 A MY119276 A MY 119276A MY PI97000683 A MYPI97000683 A MY PI97000683A MY PI9700683 A MYPI9700683 A MY PI9700683A MY 119276 A MY119276 A MY 119276A
Authority
MY
Malaysia
Prior art keywords
peptide
pharmaceutical composition
adjuvants
peptides
adjuvant
Prior art date
Application number
MYPI97000683A
Other languages
English (en)
Inventor
Schmidt Walter
Birnstiel Max
Steinlein Peter
Buschle Michael
Schweighoffer Tamas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY119276(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MY119276A publication Critical patent/MY119276A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI97000683A 1996-02-24 1997-02-21 Pharmaceutical composition for immunomodulation based on peptides and adjuvants MY119276A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation

Publications (1)

Publication Number Publication Date
MY119276A true MY119276A (en) 2005-04-30

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97000683A MY119276A (en) 1996-02-24 1997-02-21 Pharmaceutical composition for immunomodulation based on peptides and adjuvants

Country Status (34)

Country Link
US (1) US7105162B1 (OSRAM)
EP (1) EP0881906B2 (OSRAM)
JP (1) JP4184433B2 (OSRAM)
KR (1) KR100457647B1 (OSRAM)
CN (1) CN1177610C (OSRAM)
AR (1) AR005945A1 (OSRAM)
AT (1) ATE274350T1 (OSRAM)
AU (1) AU722264B2 (OSRAM)
BG (1) BG63682B1 (OSRAM)
BR (1) BR9707694A (OSRAM)
CA (1) CA2243559C (OSRAM)
CO (1) CO4600681A1 (OSRAM)
CZ (1) CZ295396B6 (OSRAM)
DE (1) DE59711873D1 (OSRAM)
DK (1) DK0881906T4 (OSRAM)
EE (1) EE04481B1 (OSRAM)
ES (1) ES2225951T5 (OSRAM)
HR (1) HRP970100B1 (OSRAM)
HU (1) HU224410B1 (OSRAM)
ID (1) ID16038A (OSRAM)
IL (1) IL125361A (OSRAM)
MY (1) MY119276A (OSRAM)
NO (1) NO983850L (OSRAM)
NZ (1) NZ332020A (OSRAM)
PE (1) PE55398A1 (OSRAM)
PL (1) PL189413B1 (OSRAM)
PT (1) PT881906E (OSRAM)
RO (1) RO119344B1 (OSRAM)
RS (1) RS50101B (OSRAM)
SI (1) SI0881906T2 (OSRAM)
SK (1) SK284582B6 (OSRAM)
TR (1) TR199801649T2 (OSRAM)
TW (1) TW585774B (OSRAM)
WO (1) WO1997030721A1 (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1061951B1 (en) * 1998-02-25 2003-08-27 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
ATE356620T1 (de) * 1998-04-20 2007-04-15 Torrey Pines Inst Topische immunostimulierung zur induzierung der migration der langerhanszellen
NZ513935A (en) * 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
CA2433794A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP1450821A1 (en) * 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
CN102174533A (zh) 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
AU2004218284B2 (en) 2003-03-04 2009-07-23 Intercell Ag Streptococcus pyogenes antigens
JP4676426B2 (ja) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト 改良型ワクチン
EP2182065A3 (en) 2003-03-31 2010-09-15 Intercell AG Staphylococcus epidermidis antigens
EP2311987A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
US7438912B2 (en) 2003-05-07 2008-10-21 Intercell Ag S.agalactiae antigens I + II
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
AU2004255456B2 (en) 2003-07-11 2010-06-24 Intercell Ag HCV vaccines
US20080145383A1 (en) 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ES2344739T3 (es) 2004-09-24 2010-09-06 Intercell Ag Proteina capsidial vp1 modificada del parvovirus b19.
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten
ES2396240T3 (es) 2005-04-20 2013-02-20 Mitsuru Akashi Poliaminoácido para usar como adyuvante
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2489673A3 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
CN101883782A (zh) 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
CA2719059C (en) * 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
CA2745205A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl trna synthetase (gts) fragments
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
US8858958B2 (en) * 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
EP3205661B1 (en) 2014-10-07 2021-07-07 Cytlimic Inc. Hsp70-derived immunity inducing peptide
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
CN108368260B (zh) * 2015-12-16 2020-09-29 休伯特保健公司 含有角鲨烯的基于两亲性聚氨基酸聚合物的疫苗佐剂组合物
JP6710004B2 (ja) * 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
EP3463440A4 (en) * 2016-05-27 2020-04-15 Etubics Corporation NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
CA3039033A1 (en) * 2016-10-11 2018-04-19 Cytlimic Inc. Medicine
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (OSRAM) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
IL82841A (en) 1986-06-13 1992-11-15 Oncogen Ligands and in vitro methods for augmenting b-cell proliferation
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
WO1991009869A1 (en) 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ5191U1 (cs) 1993-07-12 1996-09-12 Aliatros Medical, A.S. Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
RO119344B1 (ro) 2004-08-30
BG102714A (en) 1999-06-30
CN1177610C (zh) 2004-12-01
DE59711873D1 (de) 2004-09-30
EE9800255A (et) 1999-02-15
ES2225951T3 (es) 2005-03-16
YU6297A (sh) 1999-09-27
AU1875997A (en) 1997-09-10
CZ295396B6 (cs) 2005-08-17
JP4184433B2 (ja) 2008-11-19
BG63682B1 (bg) 2002-09-30
TW585774B (en) 2004-05-01
PL328455A1 (en) 1999-02-01
DK0881906T3 (da) 2004-12-20
SI0881906T1 (en) 2004-12-31
JP2000506125A (ja) 2000-05-23
EE04481B1 (et) 2005-06-15
EP0881906B1 (de) 2004-08-25
RS50101B (sr) 2009-01-22
HUP9901186A3 (en) 2001-01-29
AR005945A1 (es) 1999-07-21
ATE274350T1 (de) 2004-09-15
SI0881906T2 (sl) 2009-06-30
HU224410B1 (hu) 2005-08-29
DK0881906T4 (da) 2009-05-25
SK284582B6 (sk) 2005-07-01
WO1997030721A1 (de) 1997-08-28
PT881906E (pt) 2004-10-29
EP0881906A1 (de) 1998-12-09
ID16038A (id) 1997-08-28
CA2243559A1 (en) 1997-08-28
TR199801649T2 (xx) 1998-12-21
BR9707694A (pt) 1999-07-27
NZ332020A (en) 2000-02-28
CN1211926A (zh) 1999-03-24
PE55398A1 (es) 1998-09-22
IL125361A0 (en) 1999-03-12
PL189413B1 (pl) 2005-08-31
CZ268998A3 (cs) 1999-07-14
NO983850D0 (no) 1998-08-21
CA2243559C (en) 2011-08-09
HK1017257A1 (en) 1999-11-19
HRP970100A2 (en) 1998-04-30
CO4600681A1 (es) 1998-05-08
NO983850L (no) 1998-10-21
KR100457647B1 (ko) 2005-06-20
SK114598A3 (en) 1999-06-11
AU722264B2 (en) 2000-07-27
ES2225951T5 (es) 2009-06-15
IL125361A (en) 2002-08-14
KR19990082601A (ko) 1999-11-25
US7105162B1 (en) 2006-09-12
EP0881906B2 (de) 2009-02-04
HRP970100B1 (en) 2001-04-30
HUP9901186A2 (hu) 1999-07-28

Similar Documents

Publication Publication Date Title
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
GB2241243B (en) Rgd-containing oligopeptides for use in thrombus and tumour detection
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DE69529219D1 (en) Helicobacter proteine und impstoffe
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
PL351893A1 (en) Vaccines
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP0835133A4 (en) RECOMBINANT COMPOSITIONS AND COMBINED COMPOSITIONS OF RABIES AND SMALLPOX VIRUSES, AND USES THEREOF
AU2535997A (en) Prostate specific antigen oligo-epitope peptide
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
CA2137639A1 (en) Vaccine Composition Comprising Autologous Epidermal Growth Factor or a Fragment or a Derivate Thereof having Anti-Tumor Activity and Use Thereof in the Therapy of Malignant Diseases
GB0203420D0 (en) Peptide
PT1122262E (pt) Péptidos específicos de zonas neovasculares
GB0203419D0 (en) Peptide
AUPQ347199A0 (en) Novel polypeptide fragments
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.